Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for preventing and treating skin disease comprising substance specifically binding to vimentin-derived peptide

A skin disease and composition technology, which is applied in the field of compositions containing substances that specifically bind to vimentin-derived peptides for the prevention and treatment of skin diseases, can solve the problems of high side effects, low treatment efficiency, low possibility and the like

Pending Publication Date: 2020-05-12
疫免医学有限公司
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the possibility of completely curing such skin diseases with these treatments is quite low, and since these methods are not therapeutic agents that only target the skin tissue and skin cells in the affected area, the treatment efficiency is slightly low, and there is a possibility of side effects Relatively high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing and treating skin disease comprising substance specifically binding to vimentin-derived peptide
  • Composition for preventing and treating skin disease comprising substance specifically binding to vimentin-derived peptide
  • Composition for preventing and treating skin disease comprising substance specifically binding to vimentin-derived peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0124] Embodiment 1: Preparation of VSF (Virus Suppressor Factor)

Embodiment 1-1

[0125] Example 1-1: Preparation of chVSF (chimeric VSF)

[0126] Based on the assumption that the main functional part of mouse VSF (mVSF) is a monoclonal antibody, a mouse / human chimeric antibody (chAb) was chimerized by genetic engineering using mVSF and human immunoglobulin.

[0127] Specifically, to prepare chimeric antibodies, the constant regions of the light and heavy chains of mVSF were replaced with the constant regions (κ, γ2 or γ4) of human immunoglobulin antibodies. For chVSF, use the pCAGGS vector as a template to prepare an expression vector ( figure 1 ). The heavy chain variable region of mVSF (mVH) (SEQ ID NO:9) including SacI and KpnI restriction sites was amplified by PCR. The light chain variable region (mVL) including Clal and XhoI restriction enzyme sites (SEQ ID NO: 8) was amplified by PCR. Primers used for PCR are described in Table 1, and PCR was performed at 94°C for 45 seconds, 60°C for 45 seconds, and 72°C for 45 seconds for a total of 35 cycles, ...

Embodiment 1-2

[0131] Example 1-2: Expression of chVSF using a two-vector expression system

[0132] 15 μg of pCAGGS-GFP was transfected into HEK 293T cells using 1 mg / mL of polyethyleneimine (PEI) to examine transfection and expression levels. The chVSF prepared in Example 1-1 was transfected into HEK 293T cells in the same manner, and 6 hours later, the medium was replaced with a medium containing 2% FBS. Cell culture supernatants were collected every 3 days and impurities contained therein were removed using a 0.45 μm filter. chVSF using nProtein A Bead purification. chVSF was eluted with 0.2M glycine / HCl buffer (pH 2.5), and 1M Tris-Cl buffer (pH 9.0) was used as neutralization buffer. Specifically, after the resin was homogenized with 10 times the volume of the resin volume of 1M Tris-Cl buffer (pH 8.0), the VSF culture supernatant was passed through the column. The resultant was washed by flowing into at least 5 times the volume of 0.1M Tris-Cl buffer (pH 8.0) relative to the colu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating a skin disease, comprising a substance specifically binding to a peptide of SEQ ID NO: 1, wherein the substancespecifically binding to the peptide of SEQ ID NO: 1 of the present invention, particularly an antibody specifically binding to the peptide of SEQ ID NO: 1 or a binding fragment of said peptide, may be applied to a skin disease expressing the peptide of SEQ ID NO: 1 to effectively prevent and treat the skin disease, and thus the substance may be usefully used as a therapeutic agent for various skin diseases with no known specific causes.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating skin diseases, comprising, as an active ingredient, a substance that specifically binds to a peptide derived from isolated vimentin. Specifically, the present invention relates to a pharmaceutical composition, a cosmetic composition, A quasi-drug composition and an external skin preparation, a method for preventing or treating skin diseases, a therapeutic use thereof, and a use thereof for preparing a medicament, a cosmetic, a quasi-drug, or an external skin preparation and the like. Background technique [0002] Skin diseases refer to all abnormalities that occur in the skin of animals including humans. In modern society, with the development of industrialization, various skin diseases that have never occurred in the past have appeared due to various harmful substances. In particular, as time goes by, the proliferation or metabolism of skin cells is weakened, le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61K39/395A61K8/64A61Q19/00
CPCA61K8/64A61K38/16A61K39/395A61Q19/00A61P17/00A61P17/04A61P17/06C07K16/18C07K2317/24A61K2039/505C07K2317/41C07K2317/622A61K39/35A61P37/08A61K2035/122A61P37/06
Inventor 金允源朴成万金敏秀
Owner 疫免医学有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com